Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.58 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3206683 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10916062 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL10913507 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL10913504 | 0.98 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10914908 | 0.84 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10914911 | 0.84 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10916010 | 0.84 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL10916008 | 0.84 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Bromide SCHEMBL10915030 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL10914376 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009098453-A1 | AZONIA BICYCLOALKANES AS M3 MUSCARINIC ACETYLCHOLIN RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | CHRNB2 38/4885CHRNA4 16/4885CHRNA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.